vs
雅培（ABT）与RYTHM, Inc.（RYM）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是RYTHM, Inc.的1075.0倍（$11.5B vs $10.7M）。雅培净利率更高（15.5% vs -127.6%，领先143.1%）。RYTHM, Inc.同比增速更快（242.0% vs 4.4%）。过去两年RYTHM, Inc.的营收复合增速更高（102.6% vs 7.2%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
RYTHM Inc.是一家临床阶段生物制药企业，专注于研发和商业化针对罕见遗传性内分泌与代谢疾病的创新疗法，主要面向美国市场，服务存在未被满足医疗需求的儿童及成人患者群体。
ABT vs RYM — 直观对比
营收规模更大
ABT
是对方的1075.0倍
$10.7M
营收增速更快
RYM
高出237.6%
4.4%
净利率更高
ABT
高出143.1%
-127.6%
两年增速更快
RYM
近两年复合增速
7.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $10.7M |
| 净利润 | $1.8B | $-13.6M |
| 毛利率 | 57.0% | 75.5% |
| 营业利润率 | 19.6% | -121.5% |
| 净利率 | 15.5% | -127.6% |
| 营收同比 | 4.4% | 242.0% |
| 净利润同比 | -80.8% | 44.1% |
| 每股收益（稀释后） | $1.01 | $-6.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTRYM
| Q4 25 | $11.5B | $10.7M | ||
| Q3 25 | $11.4B | $4.0M | ||
| Q2 25 | $11.1B | $2.0M | ||
| Q1 25 | $10.4B | $538.0K | ||
| Q4 24 | $11.0B | $-7.5M | ||
| Q3 24 | $10.6B | $1.9M | ||
| Q2 24 | $10.4B | $3.0M | ||
| Q1 24 | $10.0B | $2.6M |
净利润ABTRYM
| Q4 25 | $1.8B | $-13.6M | ||
| Q3 25 | $1.6B | $-10.7M | ||
| Q2 25 | $1.8B | $-7.4M | ||
| Q1 25 | $1.3B | $-1.6M | ||
| Q4 24 | $9.2B | $-24.4M | ||
| Q3 24 | $1.6B | $-18.7M | ||
| Q2 24 | $1.3B | $-3.0M | ||
| Q1 24 | $1.2B | $4.2M |
毛利率ABTRYM
| Q4 25 | 57.0% | 75.5% | ||
| Q3 25 | 55.4% | 34.0% | ||
| Q2 25 | 56.4% | 33.4% | ||
| Q1 25 | 56.9% | 16.7% | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | 11.6% | ||
| Q2 24 | 55.6% | 37.6% | ||
| Q1 24 | 55.2% | 6.4% |
营业利润率ABTRYM
| Q4 25 | 19.6% | -121.5% | ||
| Q3 25 | 18.1% | -219.8% | ||
| Q2 25 | 18.4% | -332.9% | ||
| Q1 25 | 16.3% | -687.9% | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 17.5% | -63.1% | ||
| Q2 24 | 16.1% | -28.5% | ||
| Q1 24 | 13.9% | 13.6% |
净利率ABTRYM
| Q4 25 | 15.5% | -127.6% | ||
| Q3 25 | 14.5% | -263.8% | ||
| Q2 25 | 16.0% | -360.4% | ||
| Q1 25 | 12.8% | -302.2% | ||
| Q4 24 | 84.1% | 324.4% | ||
| Q3 24 | 15.5% | -964.4% | ||
| Q2 24 | 12.5% | -99.3% | ||
| Q1 24 | 12.3% | 163.0% |
每股收益（稀释后）ABTRYM
| Q4 25 | $1.01 | $-6.78 | ||
| Q3 25 | $0.94 | $-5.33 | ||
| Q2 25 | $1.01 | $-3.74 | ||
| Q1 25 | $0.76 | $-0.83 | ||
| Q4 24 | $5.26 | $-24.26 | ||
| Q3 24 | $0.94 | $-17.28 | ||
| Q2 24 | $0.74 | $-3.16 | ||
| Q1 24 | $0.70 | $3.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $32.2M |
| 总债务越低越好 | $12.9B | $80.6M |
| 股东权益账面价值 | $52.1B | $13.0M |
| 总资产 | $86.7B | $106.7M |
| 负债/权益比越低杠杆越低 | 0.25× | 6.19× |
8季度趋势，按日历期对齐
现金及短期投资ABTRYM
| Q4 25 | $8.9B | $32.2M | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.3B | $41.0M | ||
| Q1 25 | $6.8B | $24.4M | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | $7.8B | $267.0K | ||
| Q2 24 | $7.2B | $57.0K | ||
| Q1 24 | $6.7B | $99.0K |
总债务ABTRYM
| Q4 25 | $12.9B | $80.6M | ||
| Q3 25 | — | $90.6M | ||
| Q2 25 | — | $40.6M | ||
| Q1 25 | — | $10.6M | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $4.6M | ||
| Q1 24 | — | — |
股东权益ABTRYM
| Q4 25 | $52.1B | $13.0M | ||
| Q3 25 | $51.0B | $11.7M | ||
| Q2 25 | $50.6B | $21.0M | ||
| Q1 25 | $48.8B | $26.8M | ||
| Q4 24 | $47.7B | $28.1M | ||
| Q3 24 | $39.8B | $5.5M | ||
| Q2 24 | $39.3B | $8.5M | ||
| Q1 24 | $38.8B | $-5.5M |
总资产ABTRYM
| Q4 25 | $86.7B | $106.7M | ||
| Q3 25 | $84.2B | $115.2M | ||
| Q2 25 | $84.0B | $69.5M | ||
| Q1 25 | $81.4B | $45.6M | ||
| Q4 24 | $81.4B | $54.0M | ||
| Q3 24 | $74.4B | $39.0M | ||
| Q2 24 | $73.0B | $39.4M | ||
| Q1 24 | $72.5B | $40.6M |
负债/权益比ABTRYM
| Q4 25 | 0.25× | 6.19× | ||
| Q3 25 | — | 7.73× | ||
| Q2 25 | — | 1.94× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $-3.0M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | — |
| 自由现金流率自由现金流/营收 | 22.9% | — |
| 资本支出强度资本支出/营收 | 6.0% | — |
| 现金转化率经营现金流/净利润 | 1.87× | — |
| 过去12个月自由现金流最近4个季度 | $7.4B | — |
8季度趋势，按日历期对齐
经营现金流ABTRYM
| Q4 25 | $3.3B | $-3.0M | ||
| Q3 25 | $2.8B | $-5.4M | ||
| Q2 25 | $2.0B | $-8.4M | ||
| Q1 25 | $1.4B | $-6.7M | ||
| Q4 24 | $2.9B | $-5.3M | ||
| Q3 24 | $2.7B | $-1.4M | ||
| Q2 24 | $2.0B | $-1.8M | ||
| Q1 24 | $1.0B | $-3.0M |
自由现金流ABTRYM
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $933.0M | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | $-1.8M | ||
| Q1 24 | $627.0M | $-3.0M |
自由现金流率ABTRYM
| Q4 25 | 22.9% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 13.8% | -61.2% | ||
| Q1 24 | 6.3% | -115.1% |
资本支出强度ABTRYM
| Q4 25 | 6.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 5.1% | 0.1% | ||
| Q1 24 | 4.0% | 0.1% |
现金转化率ABTRYM
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | -0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
RYM
| Nonlicensing Revenue | $9.5M | 89% |
| Cultivation Business Discontinued Operations | $1.2M | 11% |
